SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Ripple is currently trending as the token hovers near the psychological $1.00 level, fueling intense debate between long-term holders awaiting the Clarity Act and skeptics who view the asset as a stagnant project. Community sentiment is deeply polarized, with many retail investors expressing frustration over recent price stagnation and dilution concerns, while a vocal group of bulls remains committed, viewing the current price action as a strategic accumulation phase before potential regulatory breakthroughs.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is trending as investors focus on the company's strategic pivot toward AI infrastructure following its acquisition of Northern Data, a move that has significantly expanded its GPU capacity and data center footprint. The community is actively debating the potential for a massive short squeeze due to high short interest, while simultaneously analyzing upcoming earnings and formal guidance as key catalysts for a long-term re-rating.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is seeing intense market activity following an announcement of a massive data center leasing deal with Anthropic, though investors remain sharply divided as the stock struggles to sustain the resulting price surge. The community is actively debating the impact of ongoing ATM dilution and potential institutional manipulation, with many questioning whether the long-term AI infrastructure strategy can overcome the stock's recent volatility.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the B&W segment. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is trending as investors digest a $200 million equity offering priced at $18.50, which is being viewed by many as a strategic move to fund massive expansion into AI-driven data center power infrastructure. The community is actively debating whether the dilution will create a long-term entry point or if the stocks rapid year-to-date climb has priced in the current project backlog.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently the focus of intense debate as investors weigh record revenue and a massive backlog against an earnings miss and uncertainty regarding the Neutron launch timeline. The community remains deeply divided, with bulls pointing to the company's long-term strategic vision and new product announcements, while bears focus on the gap between current valuation and profitability.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is currently facing significant market volatility as investors await phase 3 IZAR-1 trial data, with community sentiment split between frustration over delayed timelines and conviction in the company's long-term pipeline potential. Recent discussion is heavily centered on the upcoming mandatory earnings filing, which many expect to serve as a catalyst for either a major technical re-rate or further uncertainty regarding the drug's best-in-class positioning.

On Holding AG engages in the development and distribution of sports products such as footwear, apparel, and accessories for high-performance running, outdoor, all-day activities, and tennis. It sells its products worldwide through independent retailers and global distributors, its own online presence, and its own stores. The company was founded by David Allemann, Olivier Bernhard, and Caspar Coppetti in January 2010 and is headquartered in Zurich, Switzerland.

On Holding AG - Ordinary Shares Class A

On Holding AG

On Holding is experiencing significant volatility following a surprise leadership restructuring where co-founders have returned to co-CEO roles, sparking intense debate among investors regarding the company's future direction. Despite this management uncertainty, the community remains deeply divided between bulls citing long-term growth potential and brand strength, and bears reacting to the immediate price decline and concerns over management execution.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending following a major strategic deal to acquire Boeings Wisk Aero, SkyGrid, and Insitu subsidiaries, which includes Boeing taking a significant equity stake in the company. The community is actively debating the implications of this expansion into defense and autonomous technology, with bulls highlighting the acquisition of profitable revenue streams and long-term partnerships, while bears remain focused on potential dilution and the company's path to certification.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea Ltd is currently drawing investor attention as it tests key technical support levels, with bulls highlighting the stock's potential for a valuation re-rating driven by strong growth in its e-commerce and fintech segments. Market participants are actively debating the impact of recent insider selling against the long-term potential of the company's ecosystem expansion and improving unit economics.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics (DFTX) is experiencing significant market interest and price volatility as investors eagerly await Phase 3 'Voyage' topline data for their Generalized Anxiety Disorder (GAD) treatment. The community is actively discussing the potential for a major breakthrough in the neuropsychiatry sector, with many traders positioning themselves ahead of the upcoming binary catalyst, while others weigh the company's strong cash position against the competitive landscape and inherent biotech trial risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Profound Medical (PROF) Q2 Earnings Surpass Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of +218.18% and -55.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Profound Medical (PROF) Moves 8.2% Higher: Will This Strength Last?

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Wall Street Analysts See a 59.68% Upside in Profound Medical (PROF): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 59.7% in Profound Medical (PROF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Profound Medical (PROF) Reports Q1 Loss, Tops Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of +21.91% and +4.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Indivior Pharmaceuticals Inc. (INDV) Q1 Earnings and Revenues Beat Estimates

Indivior Pharmaceuticals Inc. (INDV) delivered earnings and revenue surprises of +50.78% and +18.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Profound Medical (PROF) Projected to Post Earnings on Thursday

Profound Medical (NASDAQ:PROF) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-profound-medical-corp-stock...

Why Medtech Giants Are Quietly Paying Up for AI Diagnostics

Why Medtech Giants Are Quietly Paying Up for AI Diagnostics Why Medtech Giants Are Quietly Paying Up for AI Diagnostics PR Newswire VANCOUVER, BC, April 29, 2026 ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER, BC, April 29, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary There's a...

Profound Medical (TSE:PRN) Trading Down 2.9% - Should You Sell?

Profound Medical (TSE:PRN) Trading Down 2.9% - Here's What Happened...

Profound Medical Showcases TULSA Data, AI Software Upgrades, and Reimbursement Tailwinds at Conference

Profound Medical (NASDAQ:PROF) highlighted what it described as growing clinical evidence, expanding software capabilities, and improving reimbursement dynamics for its MRI-guided "incision-free" ultrasound platform during a conference presentation led by Arun, a company executive who said he has be...

Profound Medical (NASDAQ:PROF) Shares Down 4.3% - Time to Sell?

Profound Medical (NASDAQ:PROF) Stock Price Down 4.3% - What's Next...

Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing its platform technologies. The firm’s product, the TULSA-PRO system, combines real-time MRI, robotically driven transurethral sweeping action/thermal ultrasound, and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It is also focused on developing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. The company was founded on June 13, 2008 and is headquartered in Mississauga, Canada.

Profound Medical Corp

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$7.37
Prev Close	$7.34
Open	$7.27
Dividend Yield	0.00%
50-Day Moving Average	$6.99
Beta	0.95
Avg. Volume	113,292.61
PE Ratio	-7.43

52-Week High	$8.95
52-Week Low	$3.76
Market Capitalization	$268.15M
EPS (Annual)	-$1.41
Price to Book	5.38
Revenue Per Employee	$99,370.37

Feed

News

Sentiment

Earnings

Fundamentals

Info